34 related articles for article (PubMed ID: 12809927)
1. Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.
Danielsen HE; Pradhan M; Novelli M
Nat Rev Clin Oncol; 2016 May; 13(5):291-304. PubMed ID: 26598944
[TBL] [Abstract][Full Text] [Related]
2. Emerging critical role of molecular testing in diagnostic genitourinary pathology.
Netto GJ; Cheng L
Arch Pathol Lab Med; 2012 Apr; 136(4):372-90. PubMed ID: 22458900
[TBL] [Abstract][Full Text] [Related]
3. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?
Netto GJ
Nat Rev Urol; 2011 Dec; 9(1):41-51. PubMed ID: 22158597
[TBL] [Abstract][Full Text] [Related]
4. [Bladder carcinoma cell lines as models of the pathobiology of bladder cancer. Review of the literature and establishment of a new progression series].
Hatina J; Huckenbeck W; Rieder H; Seifert HH; Schulz WA
Urologe A; 2008 Jun; 47(6):724-34. PubMed ID: 18398596
[TBL] [Abstract][Full Text] [Related]
5. DNA index determination with Automated Cellular Imaging System (ACIS) in Barrett's esophagus: comparison with CAS 200.
Huang Q; Yu C; Klein M; Fang J; Goyal RK
BMC Clin Pathol; 2005 Aug; 5():7. PubMed ID: 16095543
[TBL] [Abstract][Full Text] [Related]
6. DNA flow cytometry: an update of its use in assessing prognosis for transitional cell cancer of the bladder.
Norming U
Semin Urol; 1993 Aug; 11(3):154-63. PubMed ID: 8210836
[No Abstract] [Full Text] [Related]
7. Evaluation of DNA flow cytometry as a screening test for bladder cancer.
deVere White RW; Deitch AD
J Cell Biochem Suppl; 1992; 16I():80-4. PubMed ID: 1305694
[TBL] [Abstract][Full Text] [Related]
8. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.
Bol MG; Baak JP; van Diermen B; Buhr-Wildhagen S; Janssen EA; Kjellevold KH; Kruse AJ; Mestad O; Øgreid P
J Clin Pathol; 2003 Jun; 56(6):447-52. PubMed ID: 12783972
[TBL] [Abstract][Full Text] [Related]
9. Correlation of grade of urothelial cell carcinomas and DNA histogram features assessed by flow cytometry and automated image cytometry.
Bol MG; Baak JP; Diermen B; Janssen EA; Buhr-Wildhagen SB; Kjellevold KH
Anal Cell Pathol; 2003; 25(3):147-53. PubMed ID: 12775919
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder.
Shariat SF; Weizer AZ; Green A; Laucirica R; Frolov A; Wheeler TM; Lerner SP
Urology; 2000 Nov; 56(5):735-40. PubMed ID: 11068290
[TBL] [Abstract][Full Text] [Related]
11. S-phase fraction in superficial urothelial carcinoma of the bladder--a prospective, long-term, follow-up study.
Falkman K; Tribukait B; Nyman CR; Larsson P; Norming U
Scand J Urol Nephrol; 2004; 38(4):278-84. PubMed ID: 15669586
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer.
Bittard H; Lamy B; Billery C
J Urol; 1996 Jun; 155(6):1887-91. PubMed ID: 8618280
[TBL] [Abstract][Full Text] [Related]
13. DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality.
Baak JP; Bol MG; van Diermen B; Janssen EA; Buhr-Wildhagen SB; Mestad O; Øgreid P; Kjellevold KH
Urology; 2003 Jun; 61(6):1266-72. PubMed ID: 12809927
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
